Compile Data Set for Download or QSAR
maximum 50k data
Found 350 Enz. Inhib. hit(s) with all data for entry = 1065
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306556((1R,8S)-N-[(4-carbamimidoyl- 2,6-dimethyl-phenyl)m...)
Affinity DataIC50:  0.741nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306637((1R,8S)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  0.759nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306613((1R,8S)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  0.759nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306685((1R,8S)-N-[(4-carbamimidoyl- 2-fluorophenyl)-methy...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306708((1S,8R)-N-[(4-carbamimidoyl- phenyl)methyl]-11,12-...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306703((1S,8R)-N-[(4- carbamimidoylphenyl) methyl]-11,12-...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306565((1R,8S)-N-{[6-amino-2-methyl- 4-(propan-2-yl)-pyri...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306558((1R,8S)-N-[(4- carbamimidoylphenyl) methyl]-12-(4-...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306620((1S,8R)-N-[(4-carbamimidoyl- phenyl)methyl]-12-[(3...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306686((1R,8S)-N-[(4-carbamimidoyl- 2,6-dimethyl-phenyl)m...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306668((1S,8R)-N-[(4-carbamimidoyl-2- methylphenyl)-methy...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306581((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306538((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)meht...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306536((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306642((1R,8S)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306535((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306647((1R,8S)-N-[(4-carbamimidoyl- 2-fluorophenyl)-methy...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306648((1R,8S)-N-[(4-carbamimidoyl- 2-fluorophenyl)-methy...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306652((1R,8S)-N-((4-carbamimidoyl- 2,6-difluorophenyl)me...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306559((1R,8S)-N-[(4- carbamimidoylphenyl) methyl]-12-(2,...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306658((1R,8S)-N-[(4-carbamimidoyl-2- fluorophenyl)-methy...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306528((+-)-N-[(4-carbamimidoylphenyl) methyl]-12-(2,4- d...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306662((1R,8S)-N-[(4-carbamimidoyl- 2-methylpheny])-methy...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306663((1S,8R)-N-[(4-carbamimidoyl- phenyl)methyl]-12-(3,...)
Affinity DataIC50:  1nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306544((1R,8S)-N-[(4- carbamimidoylphenyl) methyl]-12-(2-...)
Affinity DataIC50:  1.74nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306671((+-)-N-[(4-carbamimidoylphenyl) methyl]-11,12-diet...)
Affinity DataIC50:  1.82nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306654((1R,8S)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306632((1S,8R)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306616((1R,8S)-N-[(4- carbamimidoylphenyl) methyl]-12- cy...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306593((1S,8R)-N-[(4-carbamimidoyl- phenyl)methyl]-12-(py...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306574((1S,8R)-N-[(4- carbamimidoylphenyl)methyl]- 12-(5-...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306492((+-)-N-[(6-amino-4-ethoxy-2- methylpyridin-3-yl)me...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306490((+-)-N-[(6-amino-4-methoxy-2- methylpyridin-3-yl)m...)
Affinity DataIC50:  2nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306643((1S,8R)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  2.45nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306678((+-)-N-[(6-amino-2,4-dimethyl- pyridin-3-yl)methyl...)
Affinity DataIC50:  2.69nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306497((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)-met...)
Affinity DataIC50:  3.02nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306530((+-)-N-{[6-amino-2-methyl-4- (propan-2-yl)pyridin-...)
Affinity DataIC50:  3.02nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306475((+-)-N-[(6-amino-4-methoxy- 2-methylpyridin-3-yl)m...)
Affinity DataIC50:  3.98nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306494((+-)-N-[(6-amino-4-ethyl-2- methylpyridin-3-yl)met...)
Affinity DataIC50:  3.98nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306546((+-)-N-[(4-carbamimidoylphenyl) methyl]-12-phenyl-...)
Affinity DataIC50:  4.57nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306371((+-)-N-[(6-amino-2,4- dimethylpyridin-3-yl)- methy...)
Affinity DataIC50:  4.79nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306672((+-)-N-[(4-carbamimidoyl- phenyl)methyl]-11,12- di...)
Affinity DataIC50:  4.90nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306704((+-)-N-[(4- carbamimidoylphenyl) methyl]-6-fluoro-...)
Affinity DataIC50:  5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306498((1R,8S)-N-[(6-amino-2,4- dimethylpyridin-3-yl)-met...)
Affinity DataIC50:  5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306691((1S,8R)-N-[(4-carbamimidoyl- 2,6-difluoro-phenyl)m...)
Affinity DataIC50:  5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306604((1R,8S)-N-{[6-amino-2-methyl-4- (oxan-4-yl)pyridin...)
Affinity DataIC50:  5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306625((1R,8S)-N-[(6-carbamimidoyl- pyridin-3-yl)-methyl]...)
Affinity DataIC50:  5.01nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306693((1R,8S)-N-[(4-carbamimidoyl- 3-methoxyphenyl)-meth...)
Affinity DataIC50:  5.89nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306426((+-)-N-[(6-amino-2,4- dimethylpyridin-3-yl)methyl]...)
Affinity DataIC50:  6.31nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Global Blood Therapeutics

US Patent
LigandPNGBDBM306641((1S,8R)-N-[(4- carbamimidoylphenyl) methyl]-12-(2-...)
Affinity DataIC50:  6.31nMAssay Description:The chromogenic substrate D-Pro-Phe-Arg-pNa, 2HCl (BIOPHEN CS-31(02) from Hyphen BioMed, Neuville-Sur-oise, France) was dissolved in 5 mL deionized w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 350 total ) | Next | Last >>
Jump to: